PLXProtalix BioTherapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Protalix BioTherapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX본 종목 | $218M#8 | 11.8x#2 | 3.1x#7 | 4.1x#2 | -1.2%#5 | -325.2%#14 | -10.4%#1 | -9.2%#2 | -12.3%#1 | 3#1 | 47.3%#4 | — |
| PALI | $295M#2 | 2.6x#1 | 2.4x#6 | — | — | -16.2%#6 | — | -13.8%#3 | — | — | 190.2%#1 | — |
| FATE | $303M#1 | — | 2.0x#4 | 45.6x#9 | -51.2%#8 | 26.8%#3 | -2222.4%#11 | -88.8%#8 | -102.3%#2 | — | 165.3%#2 | — |
| LCTX | $268M#3 | — | 4.4x#11 | 18.4x#8 | 53.2%#4 | -241.4%#12 | -251.6%#5 | -104.3%#10 | — | — | -23.5%#9 | — |
| STRO | $262M#4 | — | — | 2.6x#1 | 65.2%#2 | 15.9%#4 | -154.5%#4 | — | — | — | — | — |
| LIMN | $238M#5 | — | 793.1x#12 | — | — | -187.8%#11 | — | -3395.2%#12 | -170.3%#3 | — | -96.0%#14 | — |
| IVVD | $233M#6 | — | 1.3x#2 | 4.4x#3 | 110.5%#1 | 69.1%#2 | -104.0%#2 | -29.0%#4 | — | — | -31.5%#11 | — |
| ALEC | $213M#10 | — | — | 10.1x#7 | -79.1%#10 | -20.2%#8 | -741.3%#8 | — | — | — | -35.1%#12 | — |
| TARA | $217M#9 | — | 1.3x#3 | 73.8x#11 | — | -28.7%#9 | -2189.6%#10 | -35.6%#5 | — | — | 20.7%#7 | — |
| AVXL | $224M#7 | — | 2.0x#5 | — | — | -7.8%#5 | — | -41.2%#6 | — | — | -72.5%#13 | — |
| SRZN | $201M#11 | — | — | 57.8x#10 | -67.4%#9 | -280.8%#13 | -1210.6%#9 | — | — | — | 44.3%#6 | — |
| VYGR | $188M#14 | — | 1.2x#1 | 4.6x#5 | -49.5%#6 | -84.2%#10 | -326.6%#6 | -77.6%#7 | — | — | -28.7%#10 | — |
| ABOS | $193M#12 | — | 3.4x#9 | — | — | -18.6%#7 | — | -211.9%#11 | -421.4%#5 | — | 111.5%#3 | — |
| CHRS | $188M#13 | — | 3.1x#8 | 4.5x#4 | 59.8%#3 | 489.4%#1 | -429.5%#7 | 276.2%#1 | -351.2%#4 | — | -10.3%#8 | — |
| DTIL | $184M#15 | — | 4.1x#10 | 5.4x#6 | -50.1%#7 | -738.0%#15 | -152.2%#3 | -101.0%#9 | — | — | 45.8%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice